SequelSEC

MADRIGAL PHARMACEUTICALS, INC. MDGL

Pharmaceutical Preparations · CIK 0001157601 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.28B
Fiscal year ended 2026-06-30
Operating income
-$322.62M
Fiscal year ended 2026-06-30
Free cash flow
-$206.28M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$5.60BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$244.12Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue5.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity9.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth432.1%92th
CapEx / revenue0.0%9th
Operating margin-31.3%68th
SBC / revenue10.2%36th
Net margin-30.1%64th
FCF margin-19.8%61th
Current ratio4.01x53th
Long-term debt / equity0.56x52th

MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported revenue of $1.28B and net income of -$325.10M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from MADRIGAL PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MADRIGAL PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.28B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$322.62M
Net income-$325.10M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$1.01B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

MADRIGAL PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$292.73M
Total assets$1.24B
Current assets$1.20B
Total liabilities$720.92M
Current liabilities$374.20M
Total equity incl. NCI$523.72M
Temporary (mezzanine) equityUnavailable
Inventory$99.39M
Accounts receivable$192.31M
GoodwillUnavailable
Long-term debt$340.79M
Accounts payable$34.51M

Cash flow

MADRIGAL PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$197.72M
Capital expenditures$8.57M
Investing cash flow$46.97M
Financing cash flow$251.04M
Net change in cash$101.69M
Stock-based compensation$121.43M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.52M

Derived

MADRIGAL PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$206.28M
Gross marginUnavailable
Operating margin-25.1%
FCF margin-16.1%
SBC / revenue9.5%
Current ratio3.20x
Revenue YoY growth149.0%
Net margin-25.3%
R&D / revenueUnavailable
CapEx / revenue0.7%
Long-term debt / equity0.65x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MDGL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.